Impacts on patient population studies

Overview: This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.

Target population: Adults ≥ 18 years with current cancer diagnosis

Locations: Prisma Health (Upstate and Midlands); Saint Francis Hospital, Greenville; Gibbs Cancer Center, Spartanburg; Spartanburg Medical Center; MGC Hematology Oncology, Union; and Medical University of South Carolina, Charleston

Further information: Clinicaltrials.gov NCT04387656; 864-241-6251

Overview: Little is known regarding the effect of antenatal COVID-19 on pregnancy outcomes. The purpose of this study is to determine if COVID-19 alters histopathology and gene expression of the placenta, as evidenced by analysis at time of delivery. The analysis will aim to identify whether resulting abnormal placental pathology or altered metabolism is associated with severity of symptoms (specifically pneumonia, or need for admission), gestational age at onset, and/or placenta efficiency. Histological and gene expression analysis of the placental post-delivery will determine if COVID-19 alters overall placental structure, vascularization, and/or the transcriptome.

Target Population: Female Adults ≥ 18 years and older

Locations: Prisma Health–Upstate

Further information: Clinicaltrials.gov NCT04585945; 864-455-8009, Jessica.Britt@PrismaHealth.org